Illumina Tops AI Cell Challenge, but Models Struggle to Predict Biology
Corporate teams dominated the leaderboard this year, with teams from Xaira Therapeutics, Novo Nordisk, and South Korea’s AgingLab placing in the top six.
Ion Genomics With Andrew P. Han
16 posts
Corporate teams dominated the leaderboard this year, with teams from Xaira Therapeutics, Novo Nordisk, and South Korea’s AgingLab placing in the top six.
Google drops AlphaGenome 2, Illumina layoffs, 10x Genomics inks more global clinical research collabs, Ansa Bio raises $71.5M Series C, Twist Bio’s Fiscal Q4, and more.
Ansa bio has raised $211 million to date and said it quadrupled manufacturing capacity in the past year.
The German study will follow 750 patients with rheumatic diseases while the South Korean study will look at response to JAK inhibitors in alopecia areata.
The synthetic biology company hit $126.6M in revenue in its fiscal fourth quarter, with AI drug discovery as its fastest-growing segment.
Ion Genomics @AMP, Natera’s New CEO, Guardant adds epigenetics apps to Liquid 360, lots of Q3 results, MyOme licenses methylation signatures, and more.
Exome and genome test volume grew 25 percent year over year but the company trimmed its full-year exome growth outlook.
The study will enroll stage II and III colorectal cancer patients who test MRD-positive after surgery and chemotherapy.
Also: Qiagen, Sophia Genetics, BillionToOne report financial results and links to Guardant Health, Natera, 10x Genomics, Pacific Biosciences, Tempus AI.
Guardant Health raised its full-year revenue outlook to as much as $1.37 billion after Shield colorectal cancer screening test volume more than tripled.
Natera's oncology business drove quarterly revenue to $794 million and prompted a $140 million increase to full-year guidance.
The single-cell and spatial technology company reported marginal revenue growth in the third quarter and raised its full-year revenue outlook.
Instrument revenue was up in Q3, while consumables revenue slipped and the company tightened its full-year revenue outlook.
Illumina CEO says it’s ‘not about just selling sequencers’ on Q3 call, 10x Sues Waters in Europe, Ultima gets first PopSeq win, a TCR study from BioNTech and Tempus AI, and more.
The project is Phase III of Singapore's National Precision Medicine program and builds on PRECISE-SG100K.
Oncology revenue was $172.6 million, up 28 percent year over year while data & applications revenue was up 33 percent to $108.1 million.